GCL
BIOTW

Glazer Capital LLC’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Glazer Capital LLC’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-79,079
Closed -$52K – 823
2021
Q4 		$52K Buy
+79,079
New +$54.9K ﹤0.01% 735

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Glazer Capital LLC's BIOTW Position: Q1 2022 in Review

Glazer Capital LLC sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2022, closing a stake of 79,079 shares — an estimated $52K sold.

Glazer Capital LLC first reported a position in BIOTW in Q4 2021 and held it in 1 quarter. The position peaked at $52K in Q4 2021. 52 funds tracked by Wall St. Rank hold BIOTW as of Q1 2022.

  • Glazer Capital LLC reported no remaining Biotech Acquisition Company Warrant position as of Q1 2022 after selling out during the quarter.
  • Glazer Capital LLC sold 79,079 Biotech Acquisition Company Warrant shares in Q1 2022, an estimated $52K.
  • Glazer Capital LLC first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 1 quarter.
  • Glazer Capital LLC's Biotech Acquisition Company Warrant position peaked at $52K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2022.

Based on Glazer Capital LLC's 13F filing for Q1 2022, filed 17 May 2022.